Contributions
Abstract: PB1734
Type: Publication Only
Background
Primary gastric diffuse large B cell lymphoma is a relative rare type of diffuse large B cell lymphoma. Immunochemotherapy followed by consolidation radiation is the mainstay of treatment. However, the cycles of chemotherapy and the role of consolidation radiation are still under debate.
Aims
To review and analyze the treatment experience of newly diagnosed primary gastric diffuse large B cell lymphoma. We presented the treatment outcome of our institution.
Methods
We retrospectively reviewed medical records from Jan 2005 to Dec 2014 from our institution. 30 patients with primary gastric diffuse large B cell lymphoma were included. Clinical characteristics, treatment regimens, treatment response, treatment modality, and survival were analyzed.
Results
From Jan 2005 to Dec 2014, there were 30 patients with primary gastric diffuse large B cell lymphoma. Median age was 65 years of age. 53%(n=16) of patients were male. All 30 patients (100%) have received chemotherapy. 13 of them (43%) have received involved field radiation therapy(IFRT). RCHOP or RCEOP was administered in 86%(n=26) of patients. Complete response(CR) rate was 80%(n=24). 5-year survival was 69%. In patients who achieved complete response(n=24), 5-year survival for 4 cycles of chemotherapy vs 6 cycles of chemotherapy were 88% vs 86%(p=0.42), respectively. For addition of IFRT in CR patients, 5-year survival for IFRT vs no IFRT were 83% vs 90%(p=0.93), respectively. Treatment-related mortality(TRM) was 10%(n=3) and primary refractory disease was 10%(n=3). All of them are non-CR patients. Gastrointestinal bleeding which required admission occurred in 10%(n=3) of patients. In patients who developed GI bleeding, 2 of them were non-CR patients and they all died. No patient died of disease relapse after complete response.
Conclusion
In our series, the 5-year survival was good. In patients who achieved CR, cycles of chemotherapy and consolidation radiation did not make significant difference to the survival. Prevention of early mortality may improve the outcome of this disease. Gastrointestinal bleeding in treatment is rare but with high mortality.
Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Diffuse large B cell lymphoma
Abstract: PB1734
Type: Publication Only
Background
Primary gastric diffuse large B cell lymphoma is a relative rare type of diffuse large B cell lymphoma. Immunochemotherapy followed by consolidation radiation is the mainstay of treatment. However, the cycles of chemotherapy and the role of consolidation radiation are still under debate.
Aims
To review and analyze the treatment experience of newly diagnosed primary gastric diffuse large B cell lymphoma. We presented the treatment outcome of our institution.
Methods
We retrospectively reviewed medical records from Jan 2005 to Dec 2014 from our institution. 30 patients with primary gastric diffuse large B cell lymphoma were included. Clinical characteristics, treatment regimens, treatment response, treatment modality, and survival were analyzed.
Results
From Jan 2005 to Dec 2014, there were 30 patients with primary gastric diffuse large B cell lymphoma. Median age was 65 years of age. 53%(n=16) of patients were male. All 30 patients (100%) have received chemotherapy. 13 of them (43%) have received involved field radiation therapy(IFRT). RCHOP or RCEOP was administered in 86%(n=26) of patients. Complete response(CR) rate was 80%(n=24). 5-year survival was 69%. In patients who achieved complete response(n=24), 5-year survival for 4 cycles of chemotherapy vs 6 cycles of chemotherapy were 88% vs 86%(p=0.42), respectively. For addition of IFRT in CR patients, 5-year survival for IFRT vs no IFRT were 83% vs 90%(p=0.93), respectively. Treatment-related mortality(TRM) was 10%(n=3) and primary refractory disease was 10%(n=3). All of them are non-CR patients. Gastrointestinal bleeding which required admission occurred in 10%(n=3) of patients. In patients who developed GI bleeding, 2 of them were non-CR patients and they all died. No patient died of disease relapse after complete response.
Conclusion
In our series, the 5-year survival was good. In patients who achieved CR, cycles of chemotherapy and consolidation radiation did not make significant difference to the survival. Prevention of early mortality may improve the outcome of this disease. Gastrointestinal bleeding in treatment is rare but with high mortality.
Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical
Keyword(s): Diffuse large B cell lymphoma